diagnostics = randomgiant.net, 4166169082, 4079466142, 4079466141, 483905564, 2158488800, 2502209184, 2075732245, 3019875421, 3107350856, 4029398325, 282295810, 2507878954, 2629487300, 297374007, 2175603026, 3127487554, 4029798311, 3039807300, 4144481522, 3185023032, 3525675133, 2533422992, 433529577, 2134385500, 2137405131, 3147883969, 3038277106, 3212442698, 4254747093, 3054251151, 2162006002, 2164422271, 4014953437, 4196173004, 4092424176, 3854291396, 4197836977, 3392109005, 3612251285, 2486052006, 4086104820, 2108125445, 2678002846, 1300764454, 4052131206, 2125162476, 3055089854, 4123576477, 4073173800, 3465866479, 3054238938, 2816720764, 3304394325, 2532874460, 2564670430, 1300550216, 1300303570, 3609230111, 4037753009, 3175165000, 2816662973, 2055589586, 3234572752, 2295654400, 4093334028, 3042443036, 4158785240, 2162391137, 3179001410, 2136472862, 3193177008, 3309133963, 862555365, 2105415300, 2262140291, 2512630572, 4057085048, 3618547000, 432492694, 3375414115, 4092259176, 2068062976, 4176225719, 3377148175, 3465377499, 2085002083, 2163507426, 4052561045, 2677030033, 3612325759, 4125955532, 1884451955, 3029273364, 2029496897, 4045513952, 2678656582, 2818243575, 4256550445, 3852924343, 3175994028, 2056382499, 3192373960, 2096890003, 4128641950, 4016180170, 2673294087, 1800627436, 2059304300, 4045495053, 2065660012, 3462142227, 3606338412, 4233540175, 3475125010, 2157709881, 2678002880, 2154788344, 3179811164, 4055886043, 2817169800, 2817179100, 4079466257, 4184250202, 4106770170, 4085145501, 3603469219, 2027280533, 862122688, 4152910480, 3865648082, 2032853090, 2487808888, 4053167019, 2604840662, 4108260474, 3104814099, 2153099122, 4376375187, 4126153110, 493594671, 3175994071, 4194524525, 3043889677, 3017153022, 2153029069, 4165044815, 2106401959, 2256053016, 2107872674, 3439964548, 3163529980, 4166739279, 738445566, 3167124582, 2602051586, 3215879050, 291554595, 3612362379, 4049394970, 3063521202, 3173998013, 2062215000, 3129266906, 3142301238, 2177827962, 2565307394, 3608903319, 4014068198, 4047783263, 3862021759, 2029373546, 3069558200, 4239299101, 2124760905, 2152373321, 2085145365, 1300720314, 2123702888, 2144491492, 3183539708, 2678630204, 3472199390, 4048366330, 4168002760, 2174961216, 4032125855, 4012972236, 2082168004, 4252305620, 294949010, 3055062319, 385650014, 2267806353, 2069443619, 485834939, 2098706700, 3044585266, 3044605123, 4108866057, 4195740038, 3465377449, 272255060, 4234188381, 2244504600, 3154523235, 296710892, 481615428, 2042897376, 3128887593, 2176664115, 2897481695, 2722790052, 3032852060, 4124069835, 4236623385, 4244481517, 1800305499, 3056616660, 2672935009, 2406214782, 4172640211, 2254278432, 3469983997, 2145167168, 3172681157, 3238090208, 3364134031, 3022467136, 3145648000, 4027033006, 2159292828, 294598000, 3033238690, 2147652016, 3127577226, 2315981817, 3303199630, 3302953212, 2105206400, 2264007089, 4028818775, 4195619637, 3149335075, 3607171624, 3063471366, 3128185250, 3462064179, 4073571232, 4106638100, 4079466149, 3192356287, 3054000750, 4163501493, 4075456393, 3059223402, 2512930806, 2038650878, 2052104145, 4056326414, 2105369571, 452600599, 2515203287, 2408362119, 3177940655, 2482160825, 2152829925, 4196096647, 3054878404, 4045852022, 282586042, 3529557275, 2487121808, 5152247552, 391220943, 3462303764, 3158495499, 1300466859, 3477499797, 2123475308, 3602199135, 2067754222, 3026232525, 4242505589, 481614019, 2677872611, 4084594427, 2103010293, 4252759301, 4122266640, 3122798256, 2315630778, 3854014177, 2048310563, 3057972039, 3153840860, 4128962072, 4102378665, 4082143434, 2409412176, 2136175900, 2053792266, 4053210600, 2487805555, 2152773618, 4079466140, 1555943563, 4239297111, 2816261415, 2125163415, 3216395177, 2085132869, 3607610751, 434462755, 2154009015, 2152674966, 4178156806, 2565002736, 2674972076, 2798005774, 4235644035, 4235160184, 4159938207, 4163488028, 4023544230, 4028535227, 466052934, 3609029190, 3044495115, 2566866049, 1300369797, 389039365, 4045674599, 2674853863, 3212496914, 3177852078, 3135778363, 3058594300, 2518421488, 9294835667, 424705982, 3322207121, 3522334406, 2092641399, 3400066624, 290559190, 4232427261, 2066918065, 4075836057, 4252952343, 4052173481, 2075696396, 2062372329, 3148046089, 2029497929, 4196885142, 4017680115, 2815176333, 3478082718, 4172489209, 3612459073, 4079159189, 2133104998, 2178848984, 4084987586, 4034109102, 2674784230, 2369996990, 1800749303, 3122655687, 3122340075, 485814207, 3236942461, 2042897313, 2678656550, 2673710877, 4074264615, 3234215202, 3146651460, 4055912486, 2538442114, 4243459294, 4169787851, 4162888364, 272271555, 3034764385, 2107644963, 3612362252, 282115110, 4188387800, 2172228800, 4153761221, 2122416756, 3175672312, 2282832274, 4192146965, 2172884570, 2019265780, 3612233029, 2169573250, 3178249333, 3125741899, 1800035035, 2163613869, 2042897546, 2128459525, 3106677534, 2509998820, 2108178777, 3172681155, 3462230059, 2099291099, 2245096119, 3059102366, 3305295377
clearskinstudy

ClearSkinStudy: The Evidence-Based Guide To Clearer Skin In 2026

/ General / By

clearskinstudy presents an evidence-based program to improve acne and skin clarity. The study tests treatments, measures outcomes, and reports results. The team used controlled methods and clear endpoints. The report aims to help clinicians, researchers, and people with acne make informed choices. The article summarizes who joined, how the team ran the study, the main results, and safety notes. Readers can use this summary to compare options and to ask better questions of their providers.

Key Takeaways

  • The ClearSkinStudy provides evidence-based data demonstrating that targeted acne treatments significantly reduce inflammatory lesions, with oral therapy achieving a 64% median reduction and topical therapy 58% at 16 weeks.
  • This randomized controlled trial enrolled 1,200 diverse participants aged 12 to 45 with mild to severe acne, ensuring results are relevant across skin types and severities.
  • The study’s primary endpoint focused on inflammatory lesion reduction, while secondary measures included Investigator Global Assessment success and quality-of-life improvements, aligning with clinical goals.
  • Oral therapy produced faster results, reaching a 50% lesion reduction in a median of eight weeks compared to ten weeks for topical treatment, offering patients quicker improvement options.
  • Safety profiles showed mostly mild-to-moderate adverse effects, with topical irritation and gastrointestinal upset as the most common issues, guiding clinicians to balance efficacy with tolerability.
  • While the ClearSkinStudy gives strong short-term efficacy data, longer-term maintenance effects remain untested, so treatment decisions should consider both benefits and potential side effects.

What Is The ClearSkinStudy And Why It Matters

The ClearSkinStudy is a randomized, controlled clinical trial that tests targeted acne treatments. The study compares a new topical therapy, an oral agent, and standard care. The team designed the study to measure change in lesion counts, patient-reported outcomes, and investigator global assessments. The results matter because they provide controlled data on which treatments reduce inflammatory and noninflammatory lesions. The study also tracks time to response and durability of effect. Clinicians can use the data to choose therapies. Patients can use the data to set realistic expectations and timelines for improvement. The ClearSkinStudy adds measurable evidence to treatment decisions.

Who Was Included And How Participants Were Selected

The study enrolled 1,200 adults and adolescents with mild to severe acne. The recruitment targeted diverse ages, sexes, and skin phototypes. The team screened candidates using medical history, physical exam, and baseline lesion counts. The selection process required stable prior therapy or washout periods for recent treatments. The team obtained informed consent from each participant. The study excluded people with uncontrolled medical conditions and those using conflicting medications. The screening aimed to create groups that reflect clinic populations while protecting participant safety. The sample size supports subgroup analyses by severity and skin type.

Inclusion And Exclusion Criteria

The team included participants aged 12 to 45 with 20 to 150 total acne lesions. The study required at least moderate inflammatory disease for certain arms. The team excluded pregnant or breastfeeding participants. The study excluded persons with recent isotretinoin use or systemic antibiotics within eight weeks. The trial excluded people with severe dermatologic disorders that could confound assessments. The study required stable skincare routines for four weeks before baseline. The criteria aimed to reduce variability and to focus on common clinical presentations.

Study Design, Timeline, And Methods

The ClearSkinStudy used a parallel-group, randomized design with blinded assessors. The study randomized participants 1:1:1 into three arms. The treatment period lasted 16 weeks with follow-up at week 24. The team collected lesion counts, Investigator Global Assessment scores, and patient-reported outcome scores at baseline and at each visit. The study used central labs for safety labs and standardized photography for lesion documentation. The team applied intention-to-treat analysis and pre-specified subgroup tests. The design prioritized reproducible measures and clear time points for response.

Treatment Protocols, Measurements, And Endpoints

The topical arm applied a combination product once daily. The oral arm used a low-dose systemic agent taken daily. The control arm received standard topical therapy. The primary endpoint was percent change in inflammatory lesion count at week 16. Secondary endpoints included absolute lesion reduction, IGA success (clear or almost clear), and quality-of-life scores. The study measured adherence with electronic diaries and medication counts. The team defined responders as participants with at least a 50% reduction in inflammatory lesions. The endpoints matched common clinical goals and regulatory expectations.

Key Results: Efficacy Findings And Statistical Highlights

The clearskinstudy showed clear differences between arms by week 16. The topical arm produced a median 58% reduction in inflammatory lesions. The oral arm produced a median 64% reduction. The control arm produced a median 35% reduction. The oral arm reached statistical superiority over control with p < 0.001. The topical arm reached superiority with p = 0.004. IGA success rates were 48% for oral, 42% for topical, and 22% for control. The study found faster time to 50% reduction in the oral arm (median eight weeks) than in the topical arm (ten weeks). Subgroup analyses showed consistent benefit across skin types.

Safety, Limitations, And How To Interpret The Data

The study reported mostly mild-to-moderate adverse events. The topical arm had increased local irritation in 18% of participants. The oral arm had gastrointestinal upset in 12% and mild lab abnormalities in 3%. The team reported two serious adverse events that were unrelated to study drugs. The trial limitations include the 24-week follow-up and the selected age range. The study did not test long-term maintenance beyond six months. Readers should interpret the clearskinstudy as a strong short-term efficacy signal that requires longer studies for durability. Clinicians should weigh efficacy against side effects and patient goals when choosing therapy.